ES2422301T3 - Transferencia de gen mediada por vector lentiviral y usos de la misma - Google Patents

Transferencia de gen mediada por vector lentiviral y usos de la misma

Info

Publication number
ES2422301T3
ES2422301T3 ES01985065T ES01985065T ES2422301T3 ES 2422301 T3 ES2422301 T3 ES 2422301T3 ES 01985065 T ES01985065 T ES 01985065T ES 01985065 T ES01985065 T ES 01985065T ES 2422301 T3 ES2422301 T3 ES 2422301T3
Authority
ES
Spain
Prior art keywords
endostatin
lentiviral vector
domain
interferon
gene transfer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES01985065T
Other languages
English (en)
Inventor
J Timothy Stout
Binoy Appukuttan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Development Foundation
Original Assignee
Research Development Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Development Foundation filed Critical Research Development Foundation
Application granted granted Critical
Publication of ES2422301T3 publication Critical patent/ES2422301T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un vector lentiviral recombinante que comprende un primer gen terapéutico que reduce o inhibe la angiogénesisocular para uso en el tratamiento de degeneración macular relacionad con la edad en un individuo, en el que dichoprimer gen terapéutico está seleccionado del grupo que consiste en endostatina, angiostatina, endostatina XVIII,endostatina XV, el dominio de hemopexina de terminal C de la metaloproteinasa-2 matriz, el dominio kringle 5 deplasminógeno humano, la monoquina inducida por interferón-gamma (Mig), la proteína inducible por interferónalfa (IP10), FLT-1 soluble (receptor de tirosina quinasa 1 similar a fms), y el receptor de dominio de inserción dequinasa (KDR).
ES01985065T 2000-12-19 2001-12-18 Transferencia de gen mediada por vector lentiviral y usos de la misma Expired - Lifetime ES2422301T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25670100P 2000-12-19 2000-12-19
PCT/US2001/049241 WO2002049677A1 (en) 2000-12-19 2001-12-18 Lentiviral vector-mediated gene transfer and uses thereof

Publications (1)

Publication Number Publication Date
ES2422301T3 true ES2422301T3 (es) 2013-09-10

Family

ID=22973247

Family Applications (2)

Application Number Title Priority Date Filing Date
ES01985065T Expired - Lifetime ES2422301T3 (es) 2000-12-19 2001-12-18 Transferencia de gen mediada por vector lentiviral y usos de la misma
ES10177185T Expired - Lifetime ES2393717T3 (es) 2000-12-19 2001-12-18 Transferencia de gen mediada por vector lentiviral y usos de la misma

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES10177185T Expired - Lifetime ES2393717T3 (es) 2000-12-19 2001-12-18 Transferencia de gen mediada por vector lentiviral y usos de la misma

Country Status (15)

Country Link
US (1) US20020114783A1 (es)
EP (2) EP2301583B1 (es)
JP (2) JP4280496B2 (es)
KR (3) KR20080080684A (es)
CN (2) CN100591359C (es)
AU (2) AU2002234053B2 (es)
CA (1) CA2432301C (es)
DK (2) DK1343532T3 (es)
ES (2) ES2422301T3 (es)
IL (2) IL156427A0 (es)
NZ (1) NZ526558A (es)
PT (2) PT1343532E (es)
RU (1) RU2288742C2 (es)
WO (1) WO2002049677A1 (es)
ZA (1) ZA200304664B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100591359C (zh) * 2000-12-19 2010-02-24 研究发展基金会 慢病毒载体介导的基因转移及其用途
US7122181B2 (en) * 2000-12-19 2006-10-17 Research Development Foundation Lentiviral vector-mediated gene transfer and uses thereof
EP1401480B1 (en) 2001-02-22 2012-11-28 Novartis AG Viral vectors encoding endostatin in the treatment of ocular neovascularization
US20060251621A1 (en) * 2002-09-27 2006-11-09 Campochiaro Peter A Ocular gene therapy
US7601341B2 (en) * 2003-06-05 2009-10-13 Research Development Foundation Vascular endothelial growth factor fusion constructs used to inhibit osteoclastogenesis
AU2004269233A1 (en) * 2003-08-29 2005-03-10 Kaneka Corporation Method of constructing transgenic bird using lentivirus vector and transgenic bird obtained thereby
EP1881849A2 (en) * 2005-04-29 2008-01-30 Research Development Foundation Vascular targeting of ocular neovascularization
WO2008044339A1 (fr) * 2006-10-13 2008-04-17 Aqumen Biopharmaceuticals K.K. Agent thérapeutique/de prévention contenant un composé de statine, utilisé pour une maladie intraoculaire
CN101870734B (zh) * 2010-05-25 2012-06-20 北京大学 一种抑制新生血管生成的融合多肽及其编码基因与应用
RU2444734C1 (ru) * 2010-11-03 2012-03-10 ФГУ Ростовский НИИ акушерства и педиатрии Министерства по здравоохранению и социальному развитию РФ Способ прогнозирования невынашивания беременности ранних сроков инфекционного генеза
WO2015130783A1 (en) 2014-02-25 2015-09-03 Research Development Foundation Sty peptides for inhibition of angiogenesis
US11206977B2 (en) 2014-11-09 2021-12-28 The Trustees Of The University Of Pennyslvania Vision test for determining retinal disease progression
GB2547179A (en) * 2015-10-26 2017-08-16 Quethera Ltd Genetic construct
CN111398595A (zh) * 2020-02-17 2020-07-10 天津医科大学眼科医院 一种血浆小细胞外囊泡中的蛋白质tnfaip8的应用和检测方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5969120A (en) * 1993-09-03 1999-10-19 Research Development Foundation Mutants of the RB and P53 genes
US5871723A (en) * 1995-06-06 1999-02-16 The Regent Of The University Of Michigan CXC chemokines as regulators of angiogenesis
US5686414A (en) * 1995-11-14 1997-11-11 Xoma Corporation Methods of treating conditions associated with corneal transplantation
IL126626A0 (en) * 1996-05-03 1999-08-17 Abbott Lab Novel antiangiogenic peptides polynucleotides encoding same and methods for inhibiting angiogenesis
US6004798A (en) * 1997-05-14 1999-12-21 University Of Southern California Retroviral envelopes having modified hypervariable polyproline regions
JPH1180024A (ja) * 1997-09-12 1999-03-23 Toagosei Co Ltd 角膜血管新生阻害剤
CA2367375A1 (en) * 1999-03-15 2000-09-21 Chiron Corporation Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
CN100591359C (zh) * 2000-12-19 2010-02-24 研究发展基金会 慢病毒载体介导的基因转移及其用途

Also Published As

Publication number Publication date
ES2393717T3 (es) 2012-12-27
EP1343532A1 (en) 2003-09-17
CN1487841A (zh) 2004-04-07
DK1343532T3 (da) 2013-07-29
US20020114783A1 (en) 2002-08-22
KR20080080684A (ko) 2008-09-04
EP2301583A1 (en) 2011-03-30
EP1343532A4 (en) 2006-03-15
AU3405302A (en) 2002-07-01
AU2002234053B2 (en) 2004-07-15
ZA200304664B (en) 2007-02-28
RU2288742C2 (ru) 2006-12-10
KR101026078B1 (ko) 2011-03-31
JP4280496B2 (ja) 2009-06-17
CA2432301C (en) 2013-06-04
CA2432301A1 (en) 2002-06-27
CN100591359C (zh) 2010-02-24
KR20030075152A (ko) 2003-09-22
DK2301583T3 (da) 2012-12-10
CN101732731B (zh) 2013-04-10
JP2009137998A (ja) 2009-06-25
EP1343532B1 (en) 2013-04-24
IL156427A0 (en) 2004-01-04
WO2002049677A1 (en) 2002-06-27
KR20100011994A (ko) 2010-02-03
PT2301583E (pt) 2012-12-06
JP2004520307A (ja) 2004-07-08
NZ526558A (en) 2004-06-25
CN101732731A (zh) 2010-06-16
IL156427A (en) 2011-06-30
EP2301583B1 (en) 2012-08-22
PT1343532E (pt) 2013-07-29

Similar Documents

Publication Publication Date Title
ES2422301T3 (es) Transferencia de gen mediada por vector lentiviral y usos de la misma
CY1113379T1 (el) Πεπτιδια κdr και εμβολια που τα περιλαμβανουν
ES2153223T3 (es) Flavivirus quimericos y/o flavivirus de crecimiento restringido.
ATE330019T1 (de) Vektor zur gewebespezifischen replikation und expression
BR0107972A (pt) Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
BR9915210A (pt) N-aril-amidas de ácido antranìlico-e ácido tioantranìlico
ATE301201T1 (de) Für die gentherapie verwendbare plasmide
CR8255A (es) Tienopirazoles
ATE85081T1 (de) Analoge des gewebespezifischen plasminogenaktivators.
TR199701669A1 (xx) Deri preparasyonu i�in bile�imler.
WO2002044320A3 (en) Human elongase genes and uses thereof
DK1025237T3 (da) Human kontrolpunktskinase, hCDS1, præparater og fremgangsmåder
NO971341L (no) Promoter for reseptor tyrosinkinase TIE
HUP0203957A2 (hu) Az érképződést és az érrendszeri permeabilitást módosító és gátló hatóanyagok
AR002742A1 (es) Proteina reguladora del tipo adiposo, procedimiento para producir dicha proteina, formulaciones farmaceuticas que la incluyen, molecula de adn aisladaque codifica dicha proteina, vector y celulas recombinantes que comprenden dicho adn
EA200801714A1 (ru) Нетоксичные для нервной ткани плазминоген-активирующие факторы для лечения инсульта
WO2001043693A3 (en) Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef
GT200400241A (es) Prevencion y tratamiento de enfermedades cardiacas hipertensivas mediante el uso de los estrogenos selectivos8b-vinil-estra-1,3,5,(10)-trien-3,17b-diol y 17b-fluor-9a-vinil-estra-1,3,6,(10)-trien-3, 16a-diol
EP1082415A4 (en) METHOD AND COMPOSITIONS FOR MODULATING ANGIOGENESIS WITH THE TYROSINKINASE SRC
EP0707655A1 (de) Dna-expressionsvektoren zur verwendung in der gentherapeutischen behandlung von gefässerkrankungen
ES2125267T3 (es) Agentes estabilizantes de espuma y que proporcionan amargor derivados del lupulo.
ATE312179T1 (de) Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose
AR245958A1 (es) Procedimiento para la preparacion de polipeptidos de interleucina-1alfa
AR041169A1 (es) Polinucleotidos aislados que regulan la floracion de hierbas forrajeras y metodos de uso
ES2176363T3 (es) Peptidos de la proteina gag del vih, su preparacion y su uso.